Abstract | OBJECTIVE: METHODS: Sera of 130 primary and 39 overlap myositis including systemic sclerosis (13), rheumatoid arthritis (12), systemic lupus erythematosus (5) and Sjögren's syndrome (9) cases were analyzed. Antinuclear antibody, scleroderma-associated antibodies (anti-centromere, anti- topoisomerase I), anti-Jo-1, anti-PL-7, anti-PL-12, anti-Mi-2, anti-SRP and anti-PM-Scl, anti-Ku, anti-SS-A, anti-SS-B, anti-U1snRNP were tested. Autoantibody results were compared with clinical characteristics, disease course of overlap versus primary myositis patients, as well as with response to therapy. RESULTS: Associated connective tissue disease occurred in 23.1% of the patients. Myositis-associated antibodies were found in 8.5% of primary myositis patients, indicating that 11 additional primary myositis patients (23% vs. 29.6%) can be classified as overlap in all cohort according to the newly proposed diagnostic criteria. Polymyositis was found to be the most common myositis form in overlap myositis (87.2%), while scleroderma was the most common disease associated (33.3%). ANA was positive in 25.4% of primary and in 61.5% of overlap myositis cases. Altogether 39.6% of myositis patients (n=67) had autoantibodies, most commonly anti Jo-1 (18.3%) correlating with a polycyclic disease course. CONCLUSION:
|
Authors | Andrea Váncsa, Lajos Gergely, Andrea Ponyi, Gabriella Lakos, Júlia Németh, Péter Szodoray, Katalin Dankó |
Journal | Joint bone spine
(Joint Bone Spine)
Vol. 77
Issue 2
Pg. 125-30
(Mar 2010)
ISSN: 1778-7254 [Electronic] France |
PMID | 20188618
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved. |
Chemical References |
- Autoantibodies
- Immunosuppressive Agents
|
Topics |
- Adolescent
- Adult
- Aged
- Autoantibodies
(blood, immunology)
- Cross-Sectional Studies
- Dermatomyositis
(classification, drug therapy, epidemiology, immunology)
- Female
- Follow-Up Studies
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Polymyositis
(classification, drug therapy, epidemiology, immunology)
- Retrospective Studies
- Seroepidemiologic Studies
- Treatment Outcome
- Young Adult
|